RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Greer discovered that AMPA modulators could impact RD via the Pre-Botzinger complex, and thus patented the use of AMPA modulation for that purpose. Cortex owns CX717, but would not be able to market it for the RD use without a license from U.Alberta. They now have both the molecule, and an exclusive license for the RD use. I recall a small upfront payment ($250K?), I'm sure there will be milestones and small (typically 2-3%) royalties.

NeuroInvestment